Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Daiichi's Antiplatelet Agent Approved in Japan

March 25, 2014 10:52 am | News | Comments

Daiichi Sankyo Co. Ltd. announced that it has received approval from the Ministry of Health, Labor and Welfare in Japan for the antiplatelet agent Efient for the treatment of patients with ischemic heart disease undergoing percutaneous coronary intervention (PCI). Read more...

TOPICS:

EU Approves New Thyroid Cancer Indication for Cometriq

March 25, 2014 10:31 am | News | Comments

Exelixis Inc. announced that the European Commission has approved Cometriq (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC). Read more...     

TOPICS:

Discovery May Help Predict Lung Cancer Treatment Success

March 25, 2014 10:01 am | News | Comments

Scientists have discovered the structure of an abnormal protein which causes an aggressive type of lung cancer, according to new research. Read more...                             

TOPICS:
Advertisement

Agios Enrolls First Patient in Phase 1 Cancer Trial

March 24, 2014 3:23 pm | News | Comments

Agios Pharmaceuticals Inc. announced dose administration for the first patient in a Phase 1 study of AG-120 in patients with advanced solid tumors with an isocitrate dehydrogenase-1 (IDH1) mutation. Read more...           

TOPICS:

Statins May Provide Cough Relief to Lung Disease Patients

March 24, 2014 3:18 pm | News | Comments

Common cholesterol-lowering drugs could provide relief to patients suffering from a chronic lung disease, a study has shown. The drugs- known as statins- were found to help alleviate the chronic coughing associated with the disease for some patients. Read more...

TOPICS:

Pfizer Releases First Phase 3 Tofacitinib Psoriasis Results

March 24, 2014 3:01 pm | News | Comments

Pfizer Inc. announced detailed results from OPT Compare, a Phase 3 study of tofacitinib, the safety and efficacy of which are being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis. Read more...     

TOPICS:

Ariad Launches Phase 2 Lung Cancer Trial

March 24, 2014 2:46 pm | News | Comments

Ariad Pharmaceuticals Inc. announced the initiation of a pivotal global Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who were previously treated with crizotinib. Read more...    

TOPICS:

Drugs Fail to Reawaken Dormant HIV Infection

March 24, 2014 2:34 pm | News | Comments

Scientists report that compounds they hoped would “wake up” dormant reservoirs of HIV inside immune system T cells— a strategy designed to reverse latency and make the cells vulnerable to destruction— have failed to do so in laboratory tests. Read more...

TOPICS:
Advertisement

AMRI to Acquire Cedarburg Pharmaceuticals for $38.2M

March 24, 2014 2:24 pm | News | Comments

Albany Molecular Research Inc. (AMRI) announced that it has signed a definitive agreement to acquire all the outstanding shares of Cedarburg Pharmaceuticals Inc. for $38.2 million in cash. Read more...              

TOPICS:

Japan OKs World-First ADPKD Therapy

March 24, 2014 11:03 am | News | Comments

Otsuka Pharmaceutical Co. Ltd. announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kidney disease (ADPKD). Read more...         

TOPICS:

New Analyses Show Edoxaban Comparable to Warfarin

March 24, 2014 10:53 am | News | Comments

Daiichi Sankyo Co. Ltd. announced late-breaking data from two pre-specified subgroup analyses of East Asian patients with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE) enrolled in two Phase 3 edoxaban studies. Read more...

TOPICS:

Roche Chronic Hive Drug Gets FDA Green Light

March 24, 2014 10:42 am | News | Comments

Roche announced that the FDA approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives, in people 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Read more...

TOPICS:

AstraZeneca Snags Forxiga Approval in Japan

March 24, 2014 10:03 am | News | Comments

AstraZeneca announced that the Japanese Ministry of Health, Labor and Welfare approved Forxiga (dapagliflozin) as a once-daily oral treatment for type 2 diabetes. Read more...                     

TOPICS:

Simeprevir for Hepatitis C Approved in Russia

March 24, 2014 9:50 am | News | Comments

Medivir AB announced that that the Russian Ministry of Health has approved Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection. Read more...                       

TOPICS:

FDA Approves Celgene's Specialty Arthritis Drug

March 24, 2014 9:40 am | News | Comments

The Food and Drug Administration on Friday said it approved Celgene Corp.'s drug Otezla to treat adults with psoriatic arthritis, a form of arthritis that causes joint pain, stiffness and swelling in patients with psoriasis. Read more...   

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading